Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SRX246

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AzetidinesVasopressin Antagonist

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Untitled Eckardt Thesis by A. Sidwell
Traumatic brain injury (TBI) is a leading cause of death and disability in persons under 35 years of age. In nonfatal moderate to… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 4
  • figure 4
Is this relevant?
2013
2013
Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.
SRX246 is a potent, highly selective, orally bioavailable vasopressin 1a receptor antagonist that represents a novel mechanism of… Expand
Is this relevant?
2013
2013
A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
Background: We hypothesized that SRX246, a vasopressin V1a receptor antagonist, blocks the effect of intranasally administered… Expand
  • figure 1
  • table 1
  • table 2
  • figure 4
  • figure 2
Is this relevant?
2012
2012
Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.
SRX246 is a potent, highly selective human vasopressin V1a antagonist that crosses the blood-brain barrier in rats. CNS… Expand
  • figure 1
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE